| 1.85 0.06 (3.35%) | 09-26 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.78  |
1-year : | 3.32 |
| Resists | First : | 2.38 |
Second : | 2.84 |
| Pivot price | 1.81 | |||
| Supports | First : | 1.63 | Second : | 1.36 |
| MAs | MA(5) : | 1.78 |
MA(20) : | 1.82 |
| MA(100) : | 1.39 |
MA(250) : | 1.23 | |
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 38.8 |
D(3) : | 34.3 |
| RSI | RSI(14): 50.8 |
|||
| 52-week | High : | 7.48 | Low : | 0.46 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ APM ] has closed below upper band by 40.3%. Bollinger Bands are 65.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 6 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 1.85 - 1.86 | 1.86 - 1.86 |
| Low: | 1.75 - 1.76 | 1.76 - 1.77 |
| Close: | 1.84 - 1.85 | 1.85 - 1.86 |
Aptorum Group Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of infectious diseases and cancer. The company operates in the Therapeutics and Non-Therapeutics segments. Its pipeline products include SACT- 1 for neuroblastoma and other cancer types; SACT-COV19 for the treatment of coronavirus disease; ALS-4 to treat bacterial infections caused by staphylococcus aureus, including MRSA; and ALS-1 to treat viral infections caused by influenza virus A. The company is also developing ALS-2/3 for the treatment of gram+ve bacterial infections; RPIDD, a pathogen molecular diagnostic; NativusWell DOI (NLS-2), a dietary supplement; NLS-1 for the treatment of endometriosis; DLS-1+2 to treat NSCLC with mutation; DLS-3, an autoimmune small molecule; and CLS-1 for the treatment of obesity. Its pipeline products enable the discovery of new therapeutics assets, such as systematic screening of existing approved drug molecules, and microbiome-based research platforms for treatment of metabolic diseases. The company also focuses on therapeutic and diagnostic projects in neurology, gastroenterology, metabolic disorders, women's health, and other disease areas. In addition, it operates a medical clinic. Aptorum Group Limited was incorporated in 2010 and is headquartered in London, the United Kingdom.
Sat, 20 Sep 2025
Aptorum Group and DiamiR Biosciences Announce Merger Agreement - MSN
Fri, 05 Sep 2025
Aptorum Group and DiamiR Biosciences to Present at the H.C. Wainwright 27th Annual Global Investment Conference - 富途牛牛
Thu, 21 Aug 2025
Aptorum Group Merger Sparks Debate - timothysykes.com
Thu, 21 Aug 2025
Why Is Nano-Cap Aptorum Stock Rallying On Thursday? - Aptorum Group (NASDAQ:APM) - Benzinga
Thu, 21 Aug 2025
Aptorum Group’s Latest Surge: An Opportunity? - StocksToTrade
Mon, 04 Aug 2025
Aptorum Group Regains Compliance with Nasdaq's Minimum Bid Price Requirement | APM Stock News - Quiver Quantitative
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 5 (M) |
| Shares Float | 3 (M) |
| Held by Insiders | 19.4 (%) |
| Held by Institutions | 0.8 (%) |
| Shares Short | 311 (K) |
| Shares Short P.Month | 243 (K) |
| EPS | -0.78 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.76 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -8.4 % |
| Return on Equity (ttm) | -30.7 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.41 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -1 (M) |
| Levered Free Cash Flow | -2 (M) |
| PE Ratio | -2.38 |
| PEG Ratio | 0 |
| Price to Book value | 0.49 |
| Price to Sales | 0 |
| Price to Cash Flow | -8.32 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|